Genetic aspects of non-infectious endocarditis in patients with antiphospholipid syndrome

I n t r o d u c t i o n . Antiphospholipid syndrome (APS) is an autoimmune thrombophilia in which patients with clinical criteria for recurrent arterial and venous thrombosis and/or pregnancy failure show positive laboratory results for the presence of antiphospholipid antibodies (aPL). The genetic predisposition to non-infectious endocarditis (NIE) in patients with APS remains a complex and poorly understood problem.
A i m . Revealing of possible associations between polymorphisms of candidate genes and non-infectious endocarditis in patients with APS, as well as the development of possible thromboembolic complications.
M a t e r i a l s  a n d  m e t h o d s . The study involved 35 patients aged 43.0 ± 13.9 years. At the same time, the main signs characterizing NIE in APS were negative blood culture, normothermia, and the absence of obvious echoscopic signs of infection (thickening and induration calcification of the valve leaflets, minimal regurgitation). Polymorphisms of 18 genes were studied as possible molecular genetic markers for the development and/or protection of NIE in 35 patients with APS: the primary disorder was diagnosed in 15 patients (18.5%), secondary – in 20 patients with autoimmune pathology (24.7%).
R e s u l t s . For the first time, for polymorphisms rs6025 (1691 G>A) of the F5 gene, 4а/4b of the NOS3 gene, rs1800795 of the IL6 gene, rs1805087 (2756 A>G) of the MTR gene, a significant association with the development of vegetations on the valvular heart apparatus in APS was revealed. Two polymorphisms, rs1126643 (807 C>T) of the ITGA2 gene and rs1799889 (-675 5G>4G) of the PAI1 gene (SERPINE1), were found to be associated with thromboembolic complications (acute cerebrovascular accident) in NIE.
C o n c l u s i o n . It is reasonable to perform genotyping of some single nucleotide polymorphisms in patients with APS.

1. Lopes M.R.U., Danowski A., Funke A. et al. Update on antiphospholipid antibody syndrome. Rev. Assoc. Med. Bras. 2017;63(11):994–999. DOI: 10.1590/18069282.63.11.994.

2. Gaddh M., Cheng E., Elsebaie M.A.T., Bodó I. Clinical utilization and cost of thrombophilia testing in patients with venous thromboembolism. TH Open. 2020;4(3):е153–е162. DOI: 10.1055/s-0040-1714334.

3. Sciascia S., Amigo M.C., Roccatello D., Khamashta M. Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances. Nat. Rev. Rheumatol. 2017;13(9):548–560. DOI: 10.1038/nrrheum.2017.124.

4. Fanouriakis A., Kostopoulou M., Alunno A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78(6):736–745. DOI: 10.1136/ annrheumdis-2019-21508.

5. Foley J.H., Walton B.L., Aleman M.M. et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. eBioMed. 2016;5:175–182. DOI: 10.1016/j.ebiom.2016.02.011.

6. Tedesco F., Borghi M.O., Gerosa M. et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front. Immunol. 2018;9:1388. DOI: 10.3389/fimmu.2018.01388.

7. Chaturvedi S., Brodsky R.A., McCrae K.R. Complement in the pathophysiology of the antiphospholipid syndrome. Front. Immunol. 2019;10:449. DOI:10.3389/fimmu.2019.00449.

8. Grosso G., Vikerfors A., Woodhams B. et al. Thrombin activatable fi brinolysis inhibitor (TAFI) – A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). Thromb. Res. 2017;158:168–173. DOI: 10.1016/j.thromres.2017.06.028.

9. Castro-Marrero J., Balada E., Vilardell-Tarrés M., Ordi-Ros J. Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br. J. Haematol. 2009;147(3):289–296. DOI: 10.1111/j.13652141.2009.07831.x.

10. Sun G., Jia Y., Meng J. et al. A genetic risk factor for thrombophilia in a Han Chinese family. Mol. Med. Rep. 2017;15(4):1668–1672. DOI: 10.3892/mmr.2017.6217.

11. Hirmerova J., Seidlerova J., Subrt I., Slechtova J. Thrombophilia testing results in patients with a first venous thromboembolic event: should the selection criteria for testing be revisited? // Int. Angiol. 2017;36(2):167–173. DOI: 10.23736/S0392-9590.16.03679-8.

12. Habib G., Lancellotti P., Antunes M.J. et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) // Eur. Heart J. 2015;36(44):3075–3128. DOI: 10.1093/eurheartj/ehv319.

13. Hmimech W., Idrissi H.H., Diakite B. et al. Association of C677T MTHFR and G20210A FII prothrombin polymorphisms with susceptibility to myocardial infarction // Biomed. Rep. 2016;5(3):361–366. DOI: 10.3892/br.2016.717.

14. Yoon U., Kwok L., Flessenkaemper I. Bilateral superficial femoral artery thrombosis in a 15-year-old caucasian male with homozygous prothrombin G20210A genotype and associated antiphospholipid syndrome // Int. J. Angiol. 2016;25(5):e100–e105. DOI: 10.1055/s-0035-1548557.